Online inquiry

IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1611MR)

This product GTTS-WQ1611MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GDF11 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005811.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10220
UniProt ID O95390
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1611MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ860MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ5422MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ10102MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ1784MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ12820MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ11661MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ907MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ5131MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW